anti-SLAMF7 CAR T cells

Anti-SLAMF7 CAR T cells are autologous or allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the signaling lymphocytic activation molecule F7 (SLAMF7, also known as CS1/CRACC/CD319), an antigen uniformly and highly expressed on multiple myeloma (MM) cells. The CAR construct incorporates T cell activation domains (commonly with CD28 and/or 4-1BB costimulatory domains). Some products include an inducible suicide gene (e.g., inducible caspase 9) to mitigate toxicity risks. The therapy recognizes and eradicates SLAMF7-expressing malignant plasma cells, and has fratricide-resistant designs due to SLAMF7 expression on endogenous immune cells. Primary clinical development is in relapse/refractory multiple myeloma, and the approach is under Phase 1 and 2 clinical investigation[1][2][3][4][5][6][7].

Other names

SLAMF7 CAR-T cellsSLAMF-7 CAR-T cellsSLAMF 7 CAR-T cellsSLAMF7 chimeric antigen receptor T cellsSLAMF-7 chimeric antigen receptor T cellsSLAMF 7 chimeric antigen receptor T cellsanti-SLAMF7 chimeric antigen receptor T cellsanti-SLAMF-7 chimeric antigen receptor T cellsanti-SLAMF 7 chimeric antigen receptor T cells